Nplate® (romiplostim) – New indication
January 28, 2021 - The FDA approved Amgen’s Nplate (romiplostim), to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation.
Download PDF
